Early prediction of outcome in score-identified, postcardiac surgical patients at high risk for sepsis, using soluble tumor necrosis factor receptor-p55 concentrations

Critical Care Medicine

Volumn 24, Issue 4, 1996, Pages 596-600

  Pilz, Günter ^a   Fraunberger, Peter ^a   Appel, Roland ^a   Kreuzer, Eckart ^a   Werdan, Karl ^a   Walli, Autar ^a   Seidel, Dietrich ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

heart surgery; intensive care unit; predictive value of tests; prognosis; receiver operating characteristic curve; risk; sepsis; severity of illness index; tumor necrosis factor; tumor necrosis factor receptor

Indexed keywords

TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; EARLY DIAGNOSIS; HIGH RISK POPULATION; HUMAN; INFECTION RISK; MORTALITY; OPEN HEART SURGERY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; SEPSIS; STATISTICAL ANALYSIS;

ANTIGENS, CD; APACHE; CARDIAC SURGICAL PROCEDURES; CHI-SQUARE DISTRIBUTION; HUMANS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RISK FACTORS; ROC CURVE; SEPSIS; SOLUBILITY; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 0029958774     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199604000-00008     Document Type: Article

References (30)

1. Giroir BP: Mediators of septic shock: New approaches for interrupting the endogenous inflammatory cascade. Crit Care Med 1993; 21:780-789
2. Olsson I, Lantz M, Nilsson E, et al: Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989; 42:270-275
3. Seckinger P, Isaaz S, Dayer JM: Purification and biologic characterization of a specific tumor necrosis factor α inhibitor. J Biol Chem 1989; 264:11966-11973
4. Engelmann H, Aderka D, Rubinstein M, et al: A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989;264:11974-11980
5. Lantz M, Gullberg U, Nilsson E, et al: Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor. J Clin Invest 1990; 86: 1396-1402
6. Loetscher H, Pan YCE, Lahm HW, et al: Molecular cloning and expression of the human 55 kD tumor necrosis factor receptor. Cell 1990; 61:351-359
7. Kohno T, Brewer MT, Baker SL, et al: A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci USA 1990; 87: 8331-8335
8. van Zee KJ, Kohno T, Fischer E, et al: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-α in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89:4845-4849
9. Shapiro L, Clark BD, Orencole SF, et al: Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. J Infect Dis 1993; 167:1344-1350
10. Girardin E, Roux-Lombard P, Grau GE, et al: Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 1992; 76:20-23
11. Kern P, Hemmer CJ, Gallati H, et al: Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria. J Infect Dis 1992; 166:930-934
12. van der Poll T, Jansen J, van Leenen D, et al: Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 1993; 168:955-960
13. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
14. Pilz G, Kreuzer E, Kääb S, et al: Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified high-risk patients. Chest 1994; 105: 76-82
15. Kirklin JK, Westaby S, Blackstone EH, et al: Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86: 845-857
16. Pilz G, Kääb S, Kreuzer E, et al: Evaluation of definitions and parameters for sepsis assessment in patients after cardiac surgery. Infection 1994; 22:8-17
17. Jansen NJG, van Oeveren W, Gu YJ, et al: Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 1992; 54:744-748
18. Latini R, Bianchi M, Correale E, et al: Cytokines in acute myocardial infarction: Selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol 1994; 23: 1-6
19. Chollet-Martin S, Depoix JP, Hvass U, et al: Raised plasma levels of tumor necrosis factor in heart allograft rejection. Transplant Proc 1990; 22:283-286
20. Pilz G, Gurniak T, Bujdoso O, et al: A BASIC program for calculation of APACHE II and Elebute scores and sepsis evaluation in intensive care medicine. Comput Biol Med 1991; 21:143-159
21. Elebute EA, Stoner HB: The grading of sepsis. Br J Surg 1983; 70:29-31
22. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101: 1644-1655
23. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36
24. Hanley JA, McNeil BJ: A method for comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148:839-843
25. Youden WJ: Index for rating diagnostic tests. Cancer 1950; 3:32-35
26. Padalino P, Gardinali M, Catania A, et al: Tumor necrosis factor (TNF) and soluble receptor I (sTNFR-I) in sepsis and multiple organ dysfunction syndrome (MODS). Abstr. Intensive Care Med 1994; 20(Suppl):S69
27. Loetscher H, Stueber D, Banner D, et al: Human tumor necrosis factor α (TNFα) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J Biol Chem 1993; 268:26350-26357
28. Porteu F, Nathan CF: Mobilizable intracellular pool of p55 (type I) tumor necrosis factor receptors in human neutrophils. J Leukoc Biol 1992; 52:122-124
29. Porat R, Paddock HN, Schwaitzberg SD, et al: Glycosylated recombinant human tumor necrosis factor binding protein-1 reduces mortality, shock, and production of tumor necrosis factor in rabbit Escherichia coli sepsis. Crit Care Med 1995; 23:1080-1089
30. 2 fragment of an anti-tumor necrosis factor α monoclonal antibody in patients with severe sepsis: Effects on the cardiovascular system and cytokine levels. Shock 1994; 1:237-245